PRODUCT NAME
SUFENTA
Sufentanil

DOSAGE FORMS AND STRENGTHS
SUFENTA is a sterile, preservative-free, isotonic aqueous solution for intravenous or epidural use.
SUFENTA contains an amount of sufentanil citrate that is equivalent to 5 µg sufentanil per ml.

For excipients, see List of Excipients.

PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties
Pharmacotherapeutic group: opioid anesthetics, ATC Code N01AH03

Mechanism of action
Sufentanil is highly potent opioid analgesics, (7-10 times more potent than fentanyl in man) with a high safety ration (LD50/ED50 for the lowest level of analagesia) in rats; at 25,211 this ratio is higher than for fentanyl (277) and for morphine (69.5).

Intravenous sufentanil has a rapid onset of action. Limited accumulation and rapid elimination from tissue storage sites allow a rapid recovery. Depth of analgesia is dose-related and can be adjusted to the pain level of the surgical procedure.

Like other opioid analgesics, sufentanil, depending on the dose and speed of administration, can cause muscle rigidity, as well as euphoria, miosis and bradycardia.

Histamine assays have not revealed any histamine-releasing potential in patients administered SUFENTA.

All actions of sufentanil are immediately and completely reversed by a specific opioid antagonist.

Epidural Administration:
With epidural use, SUFENTA produces spinal analgesia of a rapid onset (5-10 minutes) and moderate duration (generally 4-6 hours).

Pharmacokinetics properties
Sufentanil is a synthetic opiod with µ-agonist pharmacologic effects.

Distribution
In adults, sufentanil 5 mcg/kg given intravenously is metabolized rapidly (elimination half-life 2,7 hours). The apparent volume of distribution is 2,8 L/kg and the clearance is 2,7 L/kg/min. The pharmacokinetics of sufentanil in patients over age of 70 do not differ from those in young adults. In the neonata (0-1 month) the elimination half life is about 12 hours, the volume of distribution is 4,2 L/kg and the clearance is 6,7 ml/kg/min.

Sufentanil pharmacokinetics are linear within the dose range studied.

With epidural use peak plasma concentrations are reached within 10 minutes and are 4-6 times lower than those after intravenous administration. The addition of epinephrine (50-75 µg) further reduces the initial fast absorption by 25-50%.

Plasma protein binding of sufentanil is about 92.5%. Plasma protein binding in children is lower compared to adults and increases with age. In newborns sufentanil is about 80.5% bound to proteins compared to 88.5% in infants and 91.9% in children

Metabolism
The liver and small intestine are the major sites of biotransformation. Sufentanil is metabolized mainly via the human cytochrome P450 3A4 enzyme.

Elimination
Approximately 80% of the administered dose is excreted within 24 hours and only 2% of the dose is eliminated as unchanged drug.

Special populations
Hepatic impairment
The volume of distribution is slightly increased and total clearance slightly decreased in cirrhotic patients compared to controls. This results in a significant prolongation of half-life by about 30% which warrants a longer period of postoperative surveillance (see *Warnings and Precautions*).

Renal impairment
The volume of distribution at steady state, total clearance, and terminal elimination half-life in patients on dialysis and undergoing renal transplantation are not different from healthy controls. The free fraction of sufentanil in this population is not different from healthy patients.

NON-CLINICAL INFORMATION
Preclinical effects were observed only at exposure considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.

CLINICAL INFORMATION
Indications
Intravenous SUFENTA is used both as an analgesic adjunct to nitrous oxide/oxygen and as a sole anaesthetic in ventilated patients. It is particularly suitable for longer and more painful interventions where a potent analgesic is required to help maintain good cardiovascular stability . SUFENTA is also suited for epidural administration in spinal anaesthesia.

Intravenous SUFENTA is indicated:
- as an analgesic adjunct during induction and maintenance of balanced general anaeshesia
- as an anaesthetic agent for induction and maintenance of anaesthesia in patients undergoing major surgical procedures.

Epidural SUFENTA is indicated:
- for the postoperative management of pain following general surgery, thoracic or orthopaedic procedures and caesarean section.
- as an analgesic adjunct to epidural bupivacaine during labour and vaginal deliveries.

DOSAGE AND ADMINISTRATION
The dosage of SUFENTA should be individualized according to age, body weight, physical status, underlying pathological condition, use of other drugs, and type of surgical procedure and anesthesia. The effect of the initial dose should be taken into account in determining supplemental doses.

Intravenous administration
To avoid bradycardia it is recommended to administer a small intravenous dose of an anti-cholinergic just before induction.
Droperidol may be given to prevent nausea and vomiting.

Use as analgesic adjunct
In patients undergoing general surgery, doses of SUFENTA of 0.5-5 µg/kg provide intense analgesia, reducing the sympathetic response to surgical stimulation and preserving cardiovascular stability. The duration of activity is dose-dependent. A dose of 0.5 µg/kg may be expected to last 50 minutes. Supplemental doses of 10-25 µg should be individually adjusted to the needs of each patient and to the anticipated remaining operation time.

Use as anesthetic agent
When used in doses of ≥ 8 µg/kg SUFENTA produces sleep and maintains a dose-related profound level of analgesia without the use of additional anesthetic agents. In addition sympathetic and hormonal responses to surgical stimuli are attenuated. Supplementary doses of 25-50 µg generally suffice to maintain cardiovascular stability during anesthesia.

Epidural Administration
Proper placement of a needle or catheter in the epidural space should be verified before SUFENTA is injected.

Use for postoperative management of pain
An initial dose of 30-50 µg may be expected to provide adequate pain relief for up 4-6 hours. Additional boluses of 25 µg may be administered if there is evidence of lightening of analgesia.

Use as analgesic adjunct during labor and vaginal delivery
The addition of SUFENTA 10 µg to epidural bupivacaine (0.125%-0.25%) provides a longer duration and a better quality of analgesia. If required, two subsequent injections of the combination may be given. It is recommended not to exceed a total dose of 30 µg sufentanil.

Special populations
Use in the elderly and special patient groups:
As with other opioids the dose should be reduced in elderly and in debilitated patients.

Use in children
The safety and efficacy of intravenous SUFENTA in children under 2 years of age has been documented in only a limited number of cases. For induction and maintenance of anaesthesia in children of 2-12 years of age undergoing major surgery, an anaesthetic dose of 10-20 µg/kg administered with 100% oxygen has been used. The safety and efficacy of epidural SUFENTA in paediatric patients has been documented in only a limited number of cases.

WARNINGS AND PRECAUTIONS
As with all potent opioids:

Repiratory depression is dose related and can be reversed by spesific opioid antagonists, but a repeated dose of the latter may be necessary because the respiratory depression may last longer than the duration of action of the opioid antagonist. Marked respiratory depression accompanies profound analgesia. It can persist in the postoperative period, and if SUFENTA has been given intravenously it can even recur. Therefore, patients should remain under appropriate surveillance. Resuscitation equipment and opioid antagonists should be readily available. Hyperventilation during anesthesia may alter the patient's responses to CO2, thus affecting respiration postoperatively.

Induction of muscle rigidity, which may also involve the thoracic respiratory muscles, can occur, but can be avoided by the following measures; slow IV injection (ordinarily sufficient for lower doses), premedication with benzodiazepines and the use of muscle relaxants.

Non-epileptic (myo)clonic movements can occur.

Bradycardia and possibly cardiac arrest can occur if the patients has received an insufficient amount of anticholinergic or when SUFENTA is combined with non-vagolytic muscle relaxants. Bradycardia can be treated with atropine.

Opioids may induce hypotension, especially in hypovolaemic patients. Appropriate measures to maintain a stable arterial pressure should be taken.

The use of rapid bolus injections of opioids should be avoided in patients with compromised intracerebral compliance; in such patients the transient decrease in the mean arterial pressure has occasionally been accompanied by a short-lasting reduction of the cerebral perfusion pressure.

Patients on chronic opioid therapy or with a history of opioid abuse may required higher doses.

It is recommended to reduce the dosage in the elderly and in debilitated patients. Opioids should be titrated with caution in patients with any of the following conditions: uncontrolled hypothyroidism; pulmonary disease; decreased respiratory reserve; alcoholism; impaired hepatic or renal function. Such patients also require prolonged post-operative monitoring.

With epidural administration, caution should be exercised in the presence of respiratory depression or

compromised respiratory function and in the presence of foetal distress. The patient should be closely monitored for at least 1 hour after each dose, as early respiratory depression may occur.

ADVERSE REACTIONS

Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of sufentanil based on the comprehensive assessment of the available adverse event information. A causal relationship with sufentanil cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical Trial Data

The safety of SUFENTA was evaluated in 650 sufentanil-treated subjects who participated in 6 clinical trials. Of these, 78 subjects participated in 2 trials of sufentanil administered intravenously as an anesthetic agent for induction and maintenance of anesthesia in subjects undergoing major surgical procedures (coronary artery bypass or open-heart). The remaining 572 subjects participated in 4 trials of epidural sufentanil administered as a postoperative analgesic or as an analgesic adjunct to epidural bupivacaine during labor and vaginal deliveries. These subjects took at least 1 dose of sufentanil and provided safety data. Adverse reactions that were reported for ≥ 1% of sufentanil-treated subjects in these trials are shown in Table 1.

Table 1. Adverse reactions Reported by ≥ 1% of Sufentanil-treated Subjects in 6 Clinical Trials of Sufentanil

System / Organ Class Adverse Reaction	Sufentanil (n=650) %
Nervous System Disorders	
Sedation	19.5
Tremor neonatal	4.5
Dizziness	1.4
Headache	1.4
Cardiac Disorders	
Tachycardia	1.8
Vascular Disorders	
Hypertension	4.9
Hypotension	3.2
Pallor	1.4
Respiratory, Thoracic and Mediastinal Disorders	
Cyanosis neonatal	2.0
Gastrointestinal Disorders	
Nausea	9.8
Vomiting	5.7
Skin and Subcutaneous Tissue Disorders	
Pruritus	15.2
Skin discolouration	3.1
Musculoskeletal and Connective Tissue Disorders	
Muscle twitching	2.0
Renal and Urinary Disorders	
Urinary retention	3.2
Urinary incontinence	1.5
General Disorders and Administration Site Conditions	
Pyrexia	1.7

Additional Adverse reactions that occurred in < 1% of sufentanil-treated subjects in the 6 clinical trials are listed in Table 2.

Table 2. Adverse reactions Reported by < 1% of Sufentanil-treated Subjects in 6 Clinical Trials of Sufentanil

System / Organ Class

Adverse Reaction
Infection and Infestation
Rhinitis
Immune System Disorders
Hypersensitivity
Psychiatric Disorders
Apathy
Nervousness
Nervous System Disorders
Ataxia
Dyskinesia neonatal
Dystonia
Hyperreflexia
Hypertonia
Hypokinesia neonatal
Somnolence
Eye Disorders
Visual disturbance
Cardiac Disorders
Arrhythmia *
Electrocardiogram abnormal
Atrioventricular block
Bradycardia
Cyanosis
Respiratory, Thoracic and Mediastinal Disorders
Bronchospasm
Cough
Dysphonia
Hiccups
Hypoventilation
Respiratory disorder
Skin and Subcutaneous Tissue Disorders
Dermatitis allergic*
Dry skin
Hyperhidrosis
Rash
Rash neonatal
Musculoskeletal and Connective Tissue Disorders
Back pain
Hypotonia neonatal
Muscle rigidity*
General Disorders and Administration Site Conditions
Chills
Hypothermia
Body temperature decreased
Injection site pain*
Injection site reaction
Pain
Investigations
Body temperature increased

Adverse reactions reported from only the trials of sufentanil administered intravenously as an anesthetic agent.

Postmarketing Data

Adverse reactions first identified during postmarketing experience with sufentanil citrate are included in Table 3 and Table 4. In each table, the frequencies are provided according to the following convention:

Very common ≥ 1/10
Common ≥ 1/100 and < 1/10

Uncommon	≥ 1/1000 and < 1/100
Rare	≥ 1/10000 and < 1/1000
Very rare	<1/10000, including isolated reports

In Table 3, adverse reactions are presented by frequency category based on spontaneous reporting rates, while in Table 4 the same adverse reactions are presented by frequency category based on incidence in clinical trials or epidemiological studies, when known. The frequency category "not known" is used for adverse reactions for which no valid estimate of the incidence rate can be derived from clinical trials.

Table 3. Adverse reactions Identified During Postmarketing Experience with SUFENTA by Frequency Category Estimated from Spontaneous Reporting Rates

Immune System Disorders	
Very rare	Anaphylactic shock, Anaphylactic reaction, Anaphylactoid reaction
Nervous System Disorders	
Very rare	Coma, Convulsion, Muscle contractions involuntary
Eye Disorders	
Very rare	Miosis
Cardiac Disorders	
Very rare	Cardiac arrest (see *Warnings and Precautions*)
Vascular Disorders	
Very rare	Shock
Respiratory, Thoracic and Mediastinal Disorders	
Very rare	Respiratory arrest, Apnoea, Respiratory depression, Pulmonary oedema, Laryngospasm (see *Contraindications*, and *Warnings and Precautions*)
Skin and Subcutaneous Tissue Disorders	
Very rare	Erythema
Musculoskeletal and Connective Tissue Disorders	
Very rare	Muscle spasms (see *Warnings and Precautions*)

Table 4. Adverse reactions Identified During Postmarketing Experience with SUFENTA by Frequency Category Estimated from Clinical Trials or Epidemiologic Studies

Immune System Disorders	
Not known	Anaphylactic shock, Anaphylactic reaction, Anaphylactoid reaction
Nervous System Disorders	
Not known	Coma, Convulsion, Muscle contractions involuntary
Eye Disorders	
Not known	Miosis
Cardiac Disorders	
Not known	Cardiac arrest (*Warnings and precautions*)
Vascular Disorders	
Not known	Shock
Respiratory, Thoracic and Mediastinal Disorders	
Not known	Respiratory arrest, Apnoea, Respiratory depression, Pulmonary oedema, Laryngospasm (*Contraindications*, and *Warnings and precautions*)
Skin and Subcutaneous Tissue Disorders	
Not known	Erythema
Musculoskeletal and Connective Tissue Disorders	
Not known	Muscle spasms (*Warnings and precautions*)

CONTRAINDICATIONS

SUFENTA is contraindicated in patients with known intolerance to any of its components or to other opioids.

Intravenous use in labor or before clamping of the cord during cesarean section is contraindicated due to the possibility of respiratory depression in the newborn infant. This in contrast to the epidural use in labour, during which sufentanil in doses up to 30 µg does not influence the condition of the mother or the newborn. (see Pregnancy and breast-feding).

As with other opioids administered epidurally, SUFENTA should not be given in the presence of: severe hemorrhage or shock; septicemia, infection at the injection site; disturbances in hemostasis such as thrombocytopenia and coagulaopathy; or in the presence of anticoagulant therapy or of other concomitant drug therapy or medical conditions which could contraindicate the technique of epidural administration.

INTERACTIONS
Drugs such as barbiturates, benzodiazepines, neuroleptics, halogenic gases and other, non-selective CNS depressants (e.g. alcohol) may potentiate the respiratory depression of opioid.

When patients have received such drugs, the dose of SUFENTA required will be less then usual. Likewise, following the administration of SUFENTA, the dose of other CNS-depressant drugs should be reduced.

Sufentanil is metabolized mainly via the human cytochrome P450 3A4 enzyme. However, no in-vivo inhibition by erythromycin (a known cytochrome P450 3A4 enzyme inhibitor) has been observed. Although clinical data are lacking, in-vitro data suggest that other potents cytochrome P4503A4 enzyme inhibitors (e.g. ketoconazole, itraconazole, ritonavir) may inhibit the metabolism of sufentanil. This could increase the risk of prolonged or delayed respiratory depression. The concomitant use of such drugs requires special patient care and observation; in particular, it may be necessary to lower the dose of SUFENTA.
It is usually recommended to discontinue MAO-inhibitors 2 weeks prior to any surgical or anesthetic procedure.

Pregnancy and breast-feeding
Pregnancy
Safety of intravenous sufentanil in human pregnancy has not been established although studies in animals have not demonstrated any teratogenic effecs. (see Non-Clinical Information). Sufenta has been shown to have an embryeidal effects in rats and rabbits when given in doses 2.5 times the upper human IV dose for a period of 10 dogs to over 30 dogs
As with other drugs, risk should be weighed against potential benefit to the patient.

Controlled clinical studies during labor have shown that SUFENTA added to epidural bupivacaine in total doses up to 30 µg has no detrimental effect on the mother or the newborn, but intravenous use is contraindicated not recommended in labor. Sufenta crosses the placenta. After epidural administration of a total dose not exceeding 30µg, average plasma concentrations of 0,016 ng/mL were detected in the umbilical vein. An antidote for the child should always be at hand.

Breast-feeding
SUFENTA is excreated in breast-milk. Caution should be exercised when SUFENTA is administered to a breast-feeding woman

Effects on ability to drive and use machines
Patients should drive or operate a machine only if sufficient time has elapsed after the administration of SUFENTA.

Overdosage
Symptoms and signs
An overdosage of SUFENTA manifests itself as an extension of its pharmacologic actions. Respiratory depression, which can vary in severity from bradypnea to apnea, may occur.

Treatment
In the presence of hypoventilation or apnea, oxygen should be administered and respiration should be assisted or controlled as indicated. A specific opioid antagonist, should be used as indicated to control respiratory depression. This does not preclude the use of more immediate countermeasures. The respiratory depression may last longer than the effect of the antagonist; additional doses of the latter may therefore be required. If depressed respiration associated with muscular rigidity, an intravenous neuromuscular blocking agent might be required to facilitate assisted or controlled respiration. The patient should be carefully observed; body warmth and adequate fluid intake should be maintained. If hypotension is severe or if it persists, the possibility of hypovolaemia should be considered, and if present, it should be controlled with appropriate parenteral fluid administration.

PHARMCEUTICAL INFORMATION

List of Excipients

Sodium chloride
Water for injection
Hydrochloric acid solution
Sodium hydroxide solution

STORAGE CONDITIONS

Store below 30°C, protect from light. Keep out of reach of children.

HOW SUPPLIED

SUFENTA 5 µg/ml injection
Box @ 5 ampoules @ 10 ml
Reg. No.: DNI1439800243A1

HARUS DENGAN RESEP DOKTER

Manufactured by GlaxoSmithKline Manufacturing SpA, Torrile, Italy
Imported and distributed by PT Kimia Farma (Persero) Tbk, Jl. Veteran No. 9, Jakarta 10110, Indonesia – (021) 384-7709 for Janssen Cilag a division of PT Johnson & Johnson Indonesia
For adverse event and product quality complaint, please contact: drugsafety@jacid.jnj.com or (021) 2935-3935

Based on CCDS Dec 2013